Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. The company's Chairman and CEO, Ron Bentsur, will deliver a presentation at the event scheduled for December 12, 2024, at 10 am EST.
Nuvectis Pharma (NASDAQ: NVCT), un'azienda biofarmaceutica in fase clinica specializzata in medicinali di precisione per l'oncologia, ha annunciato la sua partecipazione al 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Il presidente e CEO dell'azienda, Ron Bentsur, presenterà un intervento durante l'evento in programma per il 12 dicembre 2024, alle 10:00 EST.
Nuvectis Pharma (NASDAQ: NVCT), una empresa biofarmacéutica en etapa clínica especializada en medicamentos de precisión para la oncología, ha anunciado su participación en el 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. El presidente y CEO de la empresa, Ron Bentsur, dará una presentación en el evento programado para el 12 de diciembre de 2024, a las 10 a.m. EST.
Nuvectis Pharma (NASDAQ: NVCT), 혁신적인 항암제를 위한 정밀 의약품에 특화된 임상 단계의 바이오제약 회사가 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Ron Bentsur는 2024년 12월 12일 오전 10시 EST에 예정된 이벤트에서 발표를 진행할 것입니다.
Nuvectis Pharma (NASDAQ: NVCT), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour l'oncologie, a annoncé sa participation au 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Le président et PDG de l'entreprise, Ron Bentsur, fera une présentation lors de l'événement prévu le 12 décembre 2024, à 10 h EST.
Nuvectis Pharma (NASDAQ: NVCT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf präzisionsmedizinische Therapien für die Onkologie spezialisiert ist, hat seine Teilnahme am 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium angekündigt. Der Vorsitzende und CEO des Unternehmens, Ron Bentsur, wird am 12. Dezember 2024 um 10 Uhr EST eine Präsentation auf der Veranstaltung halten.
- None.
- None.
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium.
| Event | 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium |
| Date | 12 December 2024 |
| Time | 10 am EST |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
When is Nuvectis Pharma (NVCT) presenting at the Ladenburg Virtual Oncology Symposium?
Who will represent Nuvectis Pharma (NVCT) at the 2024 Ladenburg Symposium?
What is Nuvectis Pharma's (NVCT) primary business focus?
